Active Ingredient (In Each Patch [Transdermal System])
Oxybutynin 3.9 mg/day
The following Structured Product Label (SPL) was submitted to the FDA by Allergan, Inc. for the product Oxytrol For Women (NDC 0023-9637). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredient (in each patch [transdermal system]), purpose, use, warnings, do not use if you, ask a doctor before use if you have, ask a doctor or pharmacist before use if you are, when using this product, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Oxybutynin 3.9 mg/day
Overactive bladder treatment
For external use only
Frequent urination can also be caused by:
If you think you might have one of these conditions, it is important to see your doctor before use.
Sleepiness, dizziness, confusion, and blurry vision may occur. Do not drive or operate machinery until you know how the patch affects you.
If swallowed, get medical help or contact a Poison Control Center right away.
women 18 years of age and older:
How to use the patch:
How to dispose of a used patch:
acrylic adhesive, polyester/ethylene-vinyl acetate film, siliconized polyester film, and triacetin
Call toll-free: 1-888-OXYTROL (1-888-699-8765) between 9:00 AM and 5:00 PM Eastern Standard Time, Monday through Friday
© 2024 AbbVie. All rights reserved.
Made in USA
Distributed by: AbbVie Inc., North Chicago, IL 60064
OXYTROL and its design are trademarks of Allergan Sales, LLC, an AbbVie company.
NDC 0023-9637-04
Full Prescription Strength
OXYBUTYNIN TRANSDERMAL SYSTEM 3.9 mg/day
Overactive Bladder Treatment
Oxytrol® FOR WOMEN
RELIEF FROM
Overactive Bladder
1 Patch Treats for
4 Days/4 Nights
4 PATCHES
(Transdermal Systems)
16-Day Supply
* Please review the disclaimer below.